Eterna Therapeutics Stock Market Value
| ERNA Stock | USD 0.26 0.01 3.70% |
| Symbol | Eterna |
Eterna Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share | Quarterly Revenue Growth 8.549 | Return On Assets | Return On Equity |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Eterna Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Eterna Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Eterna Therapeutics.
| 12/13/2024 |
| 03/13/2025 |
If you would invest 0.00 in Eterna Therapeutics on December 13, 2024 and sell it all today you would earn a total of 0.00 from holding Eterna Therapeutics or generate 0.0% return on investment in Eterna Therapeutics over 90 days. Eterna Therapeutics is related to or competes with Arcus Biosciences, Cullinan Oncology, Annexon, Structure Therapeutics, Relay Therapeutics, Revelation Biosciences, and Zura Bio. Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat ... More
Eterna Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Eterna Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Eterna Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 8.56 | |||
| Information Ratio | 0.0373 | |||
| Maximum Drawdown | 71.19 | |||
| Value At Risk | (13.95) | |||
| Potential Upside | 25.0 |
Eterna Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eterna Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Eterna Therapeutics' standard deviation. In reality, there are many statistical measures that can use Eterna Therapeutics historical prices to predict the future Eterna Therapeutics' volatility.| Risk Adjusted Performance | 0.0318 | |||
| Jensen Alpha | 0.3845 | |||
| Total Risk Alpha | 2.03 | |||
| Sortino Ratio | 0.0496 | |||
| Treynor Ratio | 0.4365 |
Eterna Therapeutics Backtested Returns
Eterna Therapeutics appears to be out of control, given 3 months investment horizon. Eterna Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0333, which denotes the company had a 0.0333 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Eterna Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Eterna Therapeutics' Mean Deviation of 7.3, downside deviation of 8.56, and Coefficient Of Variation of 3693.47 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Eterna Therapeutics holds a performance score of 2. The firm shows a Beta (market volatility) of 0.68, which means possible diversification benefits within a given portfolio. As returns on the market increase, Eterna Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Eterna Therapeutics is expected to be smaller as well. Please check Eterna Therapeutics' coefficient of variation, maximum drawdown, skewness, as well as the relationship between the total risk alpha and downside variance , to make a quick decision on whether Eterna Therapeutics' price patterns will revert.
Auto-correlation | -0.59 |
Good reverse predictability
Eterna Therapeutics has good reverse predictability. Overlapping area represents the amount of predictability between Eterna Therapeutics time series from 13th of December 2024 to 27th of January 2025 and 27th of January 2025 to 13th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Eterna Therapeutics price movement. The serial correlation of -0.59 indicates that roughly 59.0% of current Eterna Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.59 | |
| Spearman Rank Test | -0.68 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Eterna Therapeutics lagged returns against current returns
Autocorrelation, which is Eterna Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Eterna Therapeutics' stock expected returns. We can calculate the autocorrelation of Eterna Therapeutics returns to help us make a trade decision. For example, suppose you find that Eterna Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Eterna Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Eterna Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Eterna Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Eterna Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Eterna Therapeutics Lagged Returns
When evaluating Eterna Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Eterna Therapeutics stock have on its future price. Eterna Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Eterna Therapeutics autocorrelation shows the relationship between Eterna Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Eterna Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out Eterna Therapeutics Correlation, Eterna Therapeutics Volatility and Eterna Therapeutics Alpha and Beta module to complement your research on Eterna Therapeutics. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Eterna Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.